Reuters logo
BRIEF-Catabasis Pharmaceuticals reports positive results from phase 2 trial of medicine for progressive muscle degeneration disease
2017年10月4日 / 上午10点02分 / 16 天前

BRIEF-Catabasis Pharmaceuticals reports positive results from phase 2 trial of medicine for progressive muscle degeneration disease

Oct 4 (Reuters) - Catabasis Pharmaceuticals Inc:

* Catabasis Pharmaceuticals reports positive results from open-label extension of phase 2 movedmd® trial evaluating Edasalonexent in duchenne muscular dystrophy and plans to initiate phase 3 clinical trial in first half 2018

* Catabasis Pharmaceuticals Inc - ‍Edasalonexent substantially slowed duchenne muscular dystrophy disease progression through 36 weeks​

* Catabasis - ‍plans to initiate a single global phase 3 trial with Edasalonexent in patients with DMD regardless of mutation type in first half of 2018​

* Catabasis Pharmaceuticals Inc - ‍expects to report top-line results from single global phase 3 trial in DMD in 2020​

* Catabasis Pharmaceuticals Inc - ‍heart rate of boys with DMD treated with Edasalonexent decreased toward “age-normative values” during treatment​

* Catabasis - ‍believe clinical heart rate observations in boys with DMD treated with Edasalonexent​ “are intriguing and warrant follow-up” Source text for Eikon: Further company coverage:

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below